John Valade, MD
Internal Medicine · Sylvania, OHNPI 1487656195
Payments from drug & device makers
Across 212 payments — averaging $16.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$648
- AbbVie$425
- Boehringer Ingelheim$395
- Pfizer$308
- Kowa Pharmaceuticals America, Inc.$226
- Amgen$224
- plus $1K from 23 others
What the payments were for
- Food & beverage$3,439100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 40 | $648 |
| AbbVie | 26 | $425 |
| Boehringer Ingelheim | 23 | $395 |
| Pfizer | 20 | $308 |
| Kowa Pharmaceuticals America, Inc. | 15 | $226 |
| Amgen | 14 | $224 |
| Novo Nordisk | 13 | $184 |
| Johnson & Johnson | 10 | $150 |
| Merck | 9 | $122 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $101 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $101 |
| Lundbeck LLC | 3 | $83 |
| Novartis | 3 | $67 |
| Astellas Pharma US Inc | 4 | $62 |
| Optinose US, Inc. | 2 | $53 |
| Exact Sciences | 3 | $50 |
| Boston Scientific | 2 | $38 |
| Grifols USA, LLC | 1 | $28 |
| Avanir Pharmaceuticals, Inc. | 1 | $20 |
| Eisai Inc. | 1 | $19 |
| Acadia Pharmaceuticals Inc | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Sumitomo Pharma America, Inc. | 1 | $18 |
| Lilly USA, LLC | 1 | $16 |
| Almatica Pharma LLC | 1 | $14 |
| Hikma Pharmaceuticals USA | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
| Nalpropion Pharmaceuticals LLC | 1 | $11 |
How this compares
$3,439 in reported general payments places this provider in the 85th percentile of 4,428 internal medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 139 | $130,641 |
| JardianceEmpagliflozin | 101 | $93,068 |
| FarxigaDapagliflozin Propanediol | 31 | $31,641 |
| XareltoRivaroxaban | 24 | $30,925 |
| OzempicSemaglutide | 12 | $17,609 |
| JanuviaSitagliptin Phosphate | 19 | $17,312 |
| RybelsusSemaglutide | 16 | $16,429 |
| EntrestoSacubitril/Valsartan | 15 | $12,968 |
| TrulicityDulaglutide | 12 | $12,706 |
| Tresiba Flextouch U-200Insulin Degludec | 15 | $11,192 |
| Repatha SureclickEvolocumab | 18 | $9,797 |
| Arnuity ElliptaFluticasone Furoate | 26 | $8,476 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 15 | $6,992 |
| Testosterone | 11 | $5,483 |
| Rosuvastatin Calcium | 238 | $3,785 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $308 | $130,641139 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $395 | $100,059116 claims |
| Novo NordiskOzempic, Rybelsus | $184 | $34,03828 claims |
| AstraZenecaFarxiga | $648 | $31,64131 claims |
| Johnson & JohnsonXarelto | $150 | $30,92524 claims |
| MerckJanuvia | $122 | $17,31219 claims |
| NovartisEntresto | $67 | $12,96815 claims |
| Lilly USA, LLCTrulicity | $16 | $12,70612 claims |
| AbbVieSynthroid | $425 | $2,24546 claims |
| Almatica Pharma LLCSertraline Hcl | $14 | $1,243111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,428 internal medicine providers in Ohio.
Other internal medicine in Sylvania
- Robert RaeSylvania$184K
- Antoinette PragalosCincinnati$27.8M
- Steven FolkerthBeavercreek$9.1M
- Charles EgerCincinnati$8.7M
- Vadim KoshkinCleveland$6.1M
- Nizar DaboulMaumee$4.7M
- Douglas LoganCincinnati$4.7M
- Seref BornovaliLoveland$4.4M
- Yevgeniy BukhmanCanton$3.7M
- Leela VrishabhendraCincinnati$3.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.